Alphalyse

What Alphalyse does

Alphalyse is a Danish contract research organization (CRO) specializing in mass spectrometry-based protein analysis for the biopharmaceutical industry, headquartered in Odense with a US subsidiary in Palo Alto, California and UK sales coverage. Founded in 2002 by Thomas Kofoed and Ejvind Mørtz, the company delivers orthogonal analytical services — most notably host cell protein (HCP) identification and quantification using LC-MS/MS — to biopharmaceutical companies, vaccine developers, advanced therapy developers (cell, gene, and bacteriophage products), and contract manufacturing organizations. The firm was the first commercial laboratory worldwide to receive approval from the Danish Medicines Agency in 2022 for GMP-validated MS-based HCP analysis as a release assay, and in 2024 co-developed the world's first GMP-validated MS-based residual enzyme analysis with 89bio.

The company operates a specialized analytical stack built around LC-MS/MS platforms including SWATH-MS (data-independent acquisition), Triple Quad 7500, ZenoTOF 7600, and Waters Acquity HPLC, combined with proprietary automated sample-preparation workflows using pipetting robots, intact protein QC standards, and a proprietary reference database (HCPedia) drawing on 750+ customer projects. Trademarked methods including ELISA-MS™ for orthogonal ELISA coverage characterization and SWATH-MS-based HCP profiling are protected as trade secrets. Quality system work targets ICH Q6B compliance, batch comparability, accelerated stability, and regulatory documentation support (BLAs/INDs), with FDA and EMA documented acceptances of MS-only HCP data.

Alphalyse generates revenue on a quote-based, project-by-project basis through direct B2B sales to enterprise biotech and pharmaceutical clients across Europe, North America, and the UK. Pricing is custom per project (Net 30 after invoice), with documented engagement values producing material client outcomes (e.g., an estimated ~$1M and one year of development time saved for one client). The company employs approximately 30 staff, including PhD-level mass spectrometry scientists, sells exclusively direct without channel partners, and combines inside sales with webinars, industry conferences (BEBPA, Bioprocessing Summit, ESAC), and content marketing as demand-generation channels. In July 2025, Alphalyse entered a partnership with Fidelio Capital Partners to accelerate global roll-out of its MS-HCP services.

Name

Alphalyse

Legal name

Alphalyse A/S

Website

https://alphalyse.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Alphalyse is a Danish contract research organization that provides mass spectrometry-based protein analysis services — specializing in host cell protein (HCP) characterization, ELISA coverage analysis, and GMP-compliant CMC testing — to biopharmaceutical, vaccine, advanced therapy, and CMO clients across Europe, North America, and the UK.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Analytical CRO Services

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Testing Laboratories (8734), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Proteomics & Mass Spectrometry Services (HLAGANAB), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)

Keywords

• Host cell protein analysis
• Mass spectrometry CRO
• Biologics characterization services
• ELISA coverage analysis
• GMP release testing

Headquarters

HQ city

Odense

HQ country

Denmark

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. CRO Protein Analysis Services: Alphalyse operates as a Contract Research Organization (CRO) providing specialized mass spectrometry-based protein analysis services on a project basis. Revenue is generated through custom analytical service projects with pricing according to quotations. Services include HCP analysis, product characterization, ELISA coverage analysis, and regulatory documentation support. The company has completed over 10,850 client projects.
2. Custom Project Pricing: Prices for custom protein analysis projects are according to quotations. Payment terms are Net 30 from date of invoicing after service completion. 1.5% interest charge per month on late invoices.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Alphalyse is a Contract Research Organization (CRO) that delivers specialized mass spectrometry-based protein analysis services to biopharmaceutical, biotech, vaccine, and advanced therapy developers. Core offerings include host cell protein (HCP) identification and quantification, ELISA characterization and HCP coverage analysis (including the proprietary ELISA-MS™ method), product characterization (intact mass, peptide mapping, amino acid analysis), batch comparability testing, accelerated stability and forced degradation studies, and GMP-compliant data generation for regulatory documentation and batch release testing.

Product overview

Alphalyse is a Contract Research Organization (CRO) providing specialized mass spectrometry-based analytical services for biologic drug development. The company operates as a services firm rather than a software platform—offering a portfolio of laboratory analysis services including Host Cell Protein (HCP) analysis by LC-MS, ELISA characterization with coverage analysis using the proprietary ELISA-MS™ method, product characterization (intact mass, peptide mapping, amino acid analysis), batch comparability testing, accelerated stability studies, and GMP-compliant release testing. The services are delivered through expert project leaders using advanced instrumentation (SWATH-MS, MRM, Triple Quad 7500, ZenoTOF 7600) with standardized SOPs. Alphalyse supports clients in biologics (recombinant proteins, monoclonal antibodies, biosimilars, bispecific antibodies), vaccines (live attenuated, recombinant VLP, inactivated), and advanced therapies (adenovirus, AAV, lentivirus, bacteriophage products).

Differentiator

Problem solved

Functional benefit

Products and services

• Host Cell Protein (HCP) Analysis MS-based identification, characterization, and quantification of individual host cell proteins for process-related impurity analysis and risk assessment, supporting biologics developers across expression systems.
• ELISA Characterization and HCP Coverage Analysis Coverage and reagent characterization service for enzyme-linked immunosorbent assays (ELISA) to ensure ELISA fitness for purpose, including the proprietary ELISA-MS™ method for identifying which individual impurities are measured by ELISA.
• Product Characterization Structural characterization of biologics including intact mass analysis, peptide mapping, and amino acid analysis for ICH Q6B compliance, providing a thorough understanding of the molecule.
• Batch Comparability Testing Quality assurance testing for comparing pre-clinical and clinical batches during process development to demonstrate manufacturing consistency.
• Accelerated Stability and Forced Degradation Studies Stability studies to identify degradation products and support regulatory documentation for biologics license applications, covering accelerated and forced degradation conditions.
• Data for Regulatory Documentation (GMP) GMP-compliant LC-MS-based HCP analysis for batch release testing and regulatory submissions including BLAs and INDs, conducted under the world's first GMP-validated MS-based HCP analysis approval.
• Amino Acid Analysis for Protein Quantification Gold standard protein quantification service providing accurate concentration determination and molar extinction coefficient determination using acidic hydrolysis, Ion-Exchange HPLC detection, and SoloVPE variable-path length measurement.
• GMP-Validated Residual Enzyme Analysis World's first GMP-validated mass spectrometry-based assay using Multiple Reaction Monitoring (MRM) for reliable identification and quantification of specific residual enzymes with low-to-sub ppm detection limits.
• HCPedia Proprietary reference database containing data from over 750 customer HCP projects, used to support client analyses and provide context for host cell protein identification and quantification.

Quantifiable outcome

• Clients estimate savings of approximately $1M and 1 year of development time using LC-MS/MS coverage method for HCP ELISA selection
• +2 more outcomes

Named customers13 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• BioGenes GmbHcoreStrategic or Co-development PartnerCollaboration on antibody development for HCP ELISA assay. BioGenes developed antibodies while Alphalyse provided LC-MS/MS analysis guidance for downstream process optimization. Achieved 77% HCP coverage with new assay.
• Eleva GmbHcoreStrategic or Co-development PartnerCase study collaboration for moss-based expression platform HCP analysis. Alphalyse provided LC-MS/MS analysis to guide process optimization after original assay coverage dropped from 91% to 44%.
• Rockland ImmunochemicalssupportingTechnology or IntegrationJoint presentation at BEBPA 2016 conference on combining platform ELISA and mass spectrometry for HCP analysis. Collaboration on low molecular weight HCP detection methods.
• University of Southern Denmark (SDU)coreStrategic or Co-development PartnerLong-standing partnership with Protein Research Group at SDU for research collaboration. Co-developed LC-MS/MS methods and jointly pursued public funding. SDU contributes 25+ years of proteomics leadership and access to advanced equipment.
• Statens Serum Institut (SSI)coreStrategic or Co-development PartnerCollaboration to improve HCP analysis for vaccine development. Alphalyse provided orthogonal LC-MS analysis providing additional information beyond process-specific ELISA, including individual HCP identities and quantities for process development.
• 89biocoreStrategic or Co-development PartnerCollaboration to develop world's first GMP-validated MS-based residual enzyme analysis. Alphalyse created LC-MS-based assay with low-to-sub ppm detection limit for liver and cardiometabolic disease therapies.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Charles River Laboratories: Global CRO with a large biologics and bioanalytical services portfolio including HCP, cell banking, and release testing. Competes with Alphalyse for biologics CMC work but as part of a much broader services menu.
• PPD (Thermo Fisher Scientific): Global clinical and bioanalytical CRO inside Thermo Fisher, with bioanalytical LC-MS/MS capabilities for PK/PD and biologics characterization. Comparable in service type but embedded in a much larger platform.
• Eurofins Scientific: Major global testing CRO with extensive bioanalytical and pharmaceutical services, including mass spectrometry-based impurity and characterization testing for biologics — overlaps with Alphalyse's LC-MS protein analysis offering.
• SGS Health & Nutrition: Operates a global life sciences testing CRO network, including bioanalytical, CMC, and biologics characterization services. Competes in the same biopharma testing space as Alphalyse at much larger scale.

Emerging players

• Gyros Protein Technologies: Provides immunoassay and peptide/protein analysis tools for biologics development. Overlaps with Alphalyse's protein analytics customers but emphasizes immunoassay instrumentation rather than LC-MS services.
• EpiThany: Emerging analytics and bioinformatics services company focused on biologics and complex therapeutics — emerging CRO-style competitor in the protein characterization and impurity analysis space.

Others

• Bio-Techne: Supplies protein-analytical reagents, ELISA kits, and proteomics tools used in HCP and biologics workflows — an enabler/supplier to the same customers Alphalyse serves, not a direct CRO competitor.
• Sartorius (BioAnalytics): Provides bioprocess and analytical instruments used in biologics CMC, including tools relevant to host cell protein analysis — adjacent supplier/partner in the MS-HCP value chain rather than a direct service competitor.

Direct peers

• Cygnus Technologies: Specializes in HCP detection and ELISA kits/reagents for biologics — the most direct comparator to Alphalyse's MS-based HCP analysis, serving the same biopharma CMC audience with complementary assay formats.
• BioGenes GmbH: Developer of HCP-specific antibodies and immunoassays for biologics manufacturing. Collaborates with Alphalyse on combined ELISA + MS HCP coverage and serves the same process-development and release-testing customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@alphalyseas3937
• LinkedInlinkedin.com/company/alphalyse-inc.
• Xx.com/Alphalyse

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alphalyse